CN Patent

CN108066343A — 一种预防或治疗肾纤维化疾病的药物

Assigned to Rui Yang (suzhou) Biological Technology Co Ltd · Expires 2018-05-25 · 8y expired

What this patent protects

本发明涉及尼达尼布及其盐或溶剂合物在制备预防或治疗肾纤维化疾病的药物中的应用。本发明在实验研究中发现尼达尼布及其盐或溶剂合物，当口服使用剂量为0.08~32毫克/人/次时，对预防或治疗肾纤维化疾病具有显著的疗效。

USPTO Abstract

本发明涉及尼达尼布及其盐或溶剂合物在制备预防或治疗肾纤维化疾病的药物中的应用。本发明在实验研究中发现尼达尼布及其盐或溶剂合物，当口服使用剂量为0.08~32毫克/人/次时，对预防或治疗肾纤维化疾病具有显著的疗效。

Drugs covered by this patent

Patent Metadata

Patent number
CN108066343A
Jurisdiction
CN
Classification
—
Expires
2018-05-25
Drug substance claim
No
Drug product claim
No
Assignee
Rui Yang (suzhou) Biological Technology Co Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.